secretoneurin is a novel prognostic cardiovascular biomarker associated with cardiomyocyte calcium handling外文参考.pdf

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY VOL. 65, NO. 4, 2015
ª 2015 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION ISSN 0735-1097/$
PUBLISHED BY ELSEVIER INC. /
Secretoneurin Is a Novel Prognostic
Cardiovascular Biomarker Associated
With Cardiomyocyte Calcium Handling
Anett Hellebø Ottesen, MSC,*yz William E. Louch, PHD,yz Cathrine R. Carlson, PHD,yz Ole . Landsverk, PHD,x
Jouni Kurola, MD, PHD,k Rune Forstrøm Johansen,{ Morten K. Moe, PHD,# Jan Magnus Aronsen, MD,yz
Arne Didrik Høiseth, MD, PHD,*z Hilde Jarstadmarken, MSC,yz Ståle Nygård, PHD,yz Magnar Bjørås, PHD,{
Ivar Sjaastad, MD, PHD,yz Ville Pettilä, MD, PHD,** Mats Stridsberg, MD, PHD,yy Torbjørn Omland, MD, PHD, MPH,*z
Geir Christensen, MD, PHD, MHA,yz Helge Røsjø, MD, PHD*z
ABSTRACT
BACKGROUND Secretoneurin (SN) levels are increased in patients with heart failure (HF), but whether SN provides
prognostic information and influences cardiomyocyte function is unknown.
OBJECTIVES This study sought to evaluate the merit of SN as a cardiovascular biomarker and assess effects of SN on
cardiomyocyte Ca2þ handling.
METHODS We assessed the association between circulating SN levels and mortality in 2 patient cohorts and the
functional properties of SN in experimental models.
RESULTS In 143 patients hospitalized for acute HF, SN levels were closely associated with mortality (n ¼ 66) during
follow-up (median 776 days; hazard ratio [lnSN]: ; 95% confidence interval: to ; p ¼ in multivariate
analysis). SN reclassified patients to their correct risk strata on top of other predictors of mortality. In 155 patients with
ventricular arrhythmia